复方苦参注射液对乙肝相关肝细胞癌患者化疗效果及T细胞免疫的影响  

Effect of Compound Kushen Injection on Chemotherapy Effect and T Cell Immunity in Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma

作　　者：吕新远[1] 戴兵[1] 刘驰[1] LV Xin-yuan;DAI Bing;LIU Chi(Ward of Liver Disease,Department of General Surgery,Nanyang Central Hospital,Nanyang 473000,China)

机构地区：[1]南阳市中心医院普通外科肝脏病区,南阳473000

出　　处：《中国合理用药探索》2023年第10期61-66,共6页Chinese Journal of Rational Drug Use

摘　　要：目的:探讨复方苦参注射液对乙型肝炎病毒(HBV)相关肝细胞癌(HCC患者化疗效果及T细胞免疫功能的影响。方法:选取2019年1月~2021年12月期间于某院确诊的106例HBV相关HCC患者作为研究对象,采用随机数字表法分为对照组与观察组,每组53例。对照组给予经导管动脉化疗栓塞(TACE)术治疗,观察组在对照组基础上加用复方苦参注射液,比较两组患者的近期疗效[客观缓解率(ORR)、疾病控制率(DCR)]、Child-Pugh肝功能分级、肝癌标志物[α-L-岩藻糖苷酶(AFU)、甲胎蛋白(AFP)]水平、T细胞亚群(CD3^(+)、CD4^(+)、CD8^(+))水平以及不良反应发生情况。结果:治疗后,两组患者ORR比较无统计学差异(P>0.05);观察组患者DCR(86.79%)高于对照组(69.81%,P<0.05);观察组Child-Pugh肝功能分级优于对照组(P<0.05);两组AFU、AFP水平均降低(P<0.05),且观察组低于对照组(P<0.05);观察组CD3^(+)、CD4^(+)水平及CD4^(+)/CD8^(+)比值高于对照组(P<0.05),CD8^(+)水平低于对照组(P<0.05)。观察组不良反应发生率低于对照组(χ^(2)=3.944,P=0.047)。结论:复方苦参注射液辅助TACE治疗HBV相关HCC,可提高化疗效果,调节患者T细胞免疫功能,降低肿瘤标记物水平及不良反应发生率。Objective:To investigate the effect of compound Kushen injection on chemotherapy effect and T cell immune function in patients with hepatitis B virus(HBV)-related hepatocellular carcinoma(HCC).Methods:A total of 106 patients with HBV-related HCC diagnosed in a hospital from January 2019 to December 2021 were divided into control group and observation group by random number table,with 53patients in each group.The control group was treated with transcatheter arterial chemoembolization(TACE),and the observation group was treated with compound Kushen injection in addition to the treatment given in the control group.The short-term response [objective response rate(ORR) and disease control rate(DCR)],Child-Pugh liver function class,levels of hepatocellular carcinoma markers [α-L-fucosidase(AFU) and alphafetoprotein(AFP)],levels of T cell subsets(CD3^(+),CD4^(+) and CD8^(+)) and adverse reactions were compared between the two groups.Results:After treatment,there was no statistically significant difference in ORR between the two groups(P>0.05).The DCR in the observation group(86.79%) was higher than that in the control group(69.81%,P<0.05).The Child-Pugh liver function class in observation group was superior than that in the control group(P<0.05).The level of AFU and AFP decreased in both groups(P<0.05),and were lower in the observation group compared with the control group(P<0.05).The levels of CD3^(+),CD4^(+)and CD4^(+)/CD8^(+) were higher in the observation group compared with the control group(P<0.05),while the level of CD8^(+) was lower than that in the control group(P<0.05).The incidence of adverse reactions in the observation group was lower than that in the control group(χ^(2)=3.944,P=0.047).Conclusion:The compound Kushen injection combined with TACE in the treatment of HBV-related HCC can improve the chemotherapy effect,regulate the of T cells immune function,and reduce both the level of carcinoma markers and the incidence of adverse reactions.

关 键 词：乙型肝炎 肝细胞癌 化疗 复方苦参注射液 T细胞免疫 

分 类 号：R735.7[医药卫生—肿瘤]